Synthetic Adrenocorticosteroids

  • Pharmacokinetics
    • Source:
      • Synthesized from cholic acid (from cattle sources) or
      • Synthesized from steroid sapogenins (diosgenin) -- plants
    • Disposition:
      • oral administration; complete absorption
      • metabolized similar to endogenous steroids
      • molecular alterations given rise to differences in:
        • affinity for mineralocorticoid or glucocorticoid receptors
        • extent of protein binding
        • stability
        • spectrum of metabolic products
      • prodrugs may be used (prednisone is converted to prednisolone)

return to main menu

Activity
Drug Anti-inflammatory Salt-retaining Dosage Forms
Short/medium-acting glucocorticoid

hydrocortisone (cortisol)

1

1

oral, injectable, topical

cortisone (Cortone)

0.8

0.8

oral, injectable, topical

prednisone (Deltasone)

4

0.3

oral

prednisolone (Prelone)

5

0.3

oral, injectable, topical

methylprednisolone (Solu-Medrol)

5

0

oral, injectable, topical

Intermediate-acting glucocorticoid

triamcinolone (Aristocort)

5

0

oral, injectable, topical

fluprednisolone

15

0

oral

Long-acting glucocorticoid

betamethasone (Celestone)

25-40

0

oral, injectable, topical

dexamethasone (Decadron)

30

0

oral, injectable, topical

Activity
Drug Anti-inflammatory Salt-retaining Dosage Forms
Mineralocorticoids

fludrocortisone (Florinef)

10

250

oral, injectable, topical

desoxycorticosterone acetate

0

20

injectable, pellets

Adapted from Table 39-1: Goldfien, A.,Adrenocorticosteroids and Adrenocortical Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, p. 640.

Clinical Pharmacology

Altered Adrenal Function: Diagnosis and Treatment

  • Primary Adrenocortical insufficiency (Addison's Disease):
    • Overview:
      • Rare; may occur at any age; affects both sexes with equal frequency
    • Etiology/Pathogenesis
      • Addison's disease is caused by progressive destruction of the adrenals (> 90% must be destroyed before symptoms of adrenal insufficiency appear)

    return to main menu

    • Adrenal gland destruction:
      •  adrenal: common site for chronic granulomatous diseases, e.g.:
        • tuberculosis (mainly)
        • histoplasmosis
        • coccidiodomycosis
        • cryptococcosis
      •  Adrenoleukodystrophy: significant demyelination -- early death and children
      •  Adrenomyeloneuropathy: mixed motor/sensory neuropathy with spastic paraplegia -- (adults)
      •  AIDS patients-- Higher likelihood of adrenal-insufficiency because:
        • cytomegalovirus frequently involves the adrenal glands:
          • CMV necrotizing adrenalitis
          • involvement with Mycobacterium avium-intracellulare, Cryptococcus, and Kaposi sarcoma
          • note: in interpreting results from adrenal function test in AIDS patients that certain medications may potentiates adrenal insufficiency including:
            1. opiates
            2. rifampin
            3. phenytoin (Dilantin)
            4. ketoconazole (Nizoral)
      • in early cases, tuberculosis caused 70%-90% of cases
      •  Most frequent cause today is idiopathic atrophy.
        • autoimmune mechanism -- most likely
        • half of patients: circulating adrenal antibodies
          • adrenal antigens, e.g.: P450c21
          • some antibodies may cause adrenal destruction
          • other antibodies may cause adrenal insufficiency by inhibiting ACTH binding
          • some individuals also have antibodies to thyroid, parathyroid, and/or gonadal tissue

        return to main menu

        • Increased likelihood of:
          1. chronic lymphocytic thyroiditis
          2. premature ovarian failure
          3. Type I diabetes mellitus
          4. hypothyroidism
          5. hyperthyroidism
        • Presence of two or more autoimmune endocrine disorders in the same patient: polyglandular autoimmune syndrome

        return to main menu

Symptoms (frequency of symptom %)

fatigue (99%)

weakness (99%)

anorexia (90%)

nausea (90%)

vomiting (90%)

weight loss (97%)

cutaneous/mucosal pigmentation (99%, 82%)

hypotension (87%,<than 110/70 mmHg)

hypoglycemia (occasionally)

return to main menu

return to main menu

Goldfien, A.,Adrenocorticosteroids and Adrenocortical Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 635-650.
Williams, G. H and Dluhy, R. G. , Diseases of the Adrenal Cortex, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 2035-2056.